More generics on Tarceva over Iressa facing patent expiration
While blockbuster targeted drugs, Roche’s ‘Tarceva’ and AstraZeneca’s ‘Iressa’ will be expired in patent, there are more pharmaceutical companies which acquired approval on Tarceva generics than the one of Iressa even if Iressa made more sales.
Tarceva and Iressa are targeted therapies for non-s...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
